Insulin glargine and malignancy: an unwarranted alarm

被引：102

作者：

Pocock, Stuart J. ^{[1
]}

Smeeth, Liam ^{[1
]}

机构：

[1] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England

来源：

LANCET | 2009年 / 374卷 / 9689期

基金：

英国惠康基金;

关键词：

RANDOMIZED-TRIALS;

D O I：

10.1016/S0140-6736(09)61307-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：511 / 513

页数：3

共 9 条

[1]

Clayton D., 1993, Statistical Models in Epidemiology, P307

[2] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes [J].

Currie, C. J. ;

Poole, C. D. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1766-1777

[3]

HEMKENS LG, 2009, DIABETOLOGIA, DOI DOI 10.1007/S00125-009-1418.4

[4] Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden [J].

Jonasson, J. M. ;

Ljung, R. ;

Talback, M. ;

Haglund, B. ;

Gudbjornsdottir, S. ;

Steineck, G. .

DIABETOLOGIA, 2009, 52 (09) :1745-1754

[5] Randomized trials or observational tribulations? [J].

Pocock, SJ ;

Elbourne, DR .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1907-1909

[6] Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study [J].

Rosenstock, J. ;

Fonseca, V. ;

McGill, J. B. ;

Riddle, M. ;

Halle, J. P. ;

Hramiak, I. ;

Johnston, P. ;

Davis, M. .

DIABETOLOGIA, 2009, 52 (09) :1971-1973

[7]

*SDRN EP GROUP, US INS GLARG CANC IN

[8] Does diabetes therapy influence the risk of cancer? [J].

Smith, U. ;

Gale, E. A. M. .

DIABETOLOGIA, 2009, 52 (09) :1699-1708

[9] When are observational studies as credible as randomised trials? [J].

Vandenbroucke, JP .

LANCET, 2004, 363 (9422) :1728-1731

← 1 →